RecruitingEarly Phase 1NCT04857502

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

99mTc-PSMA-I&Amp;S in Patients With Prostate Cancer: An Exploratory Biodistribution Study With Histopathology Validation

Sponsor

Jonsson Comprehensive Cancer Center

Enrollment

30 participants

Start Date

Apr 27, 2021

Study Type

INTERVENTIONAL

Conditions

Prostate Carcinoma Recurrent Prostate Carcinoma

Summary

This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I\&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I\&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.

Eligibility

Sex: MALE

Plain Language Summary

Simplified for easier understanding

This study is testing a new radioactive tracer called 99mTc-PSMA-I&S to see how well it can find prostate cancer that has spread to lymph nodes, with the goal of improving surgical planning using a type of nuclear imaging scan. **You may be eligible if...** - You are a man with prostate cancer (either newly diagnosed or with a recurrence) - You have already had a 68Ga-PSMA PET/CT scan that showed cancer in your lymph nodes - You are scheduled for pelvic lymph node removal surgery - You can provide informed consent **You may NOT be eligible if...** - You started new prostate cancer treatment between your PET/CT scan and the study exam - You are unwilling or unable to comply with study procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.